Caspase-4/11 promotes hyperlipidemia and chronic kidney disease-accelerated vascular inflammation by enhancing trained immunity.

In addition, mitoROS inhibitor mitoTEMPO showed a trend of inhibition of LPS transfection–induced CASP4 activation ( Figure 8C ), N-GSDMD expression on the plasma membrane ( Figure 8D ), and VCAM-1 upregulation ( Figure 8E ).

also in 53,322 other papers